March 7, 2024 Sophia Vida
Breaking News

PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease

New York, N.Y., March 07, 2024 – PRISM MarketView announces the release of an insightful interview with Lipella Pharmaceuticals’ CEO, Dr. Jonathan Kaufman, discussing the company’s recent regulatory accomplishments and how investors stand to benefit. Lipella Pharmaceuticals was recently granted Orphan Drug Designation by the FDA for LP-410, its drug candidate for oral Graft-versus-Host Disease … Continue reading “PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease”